<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35585968</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2040-6207</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Therapeutic advances in hematology</Title>
          <ISOAbbreviation>Ther Adv Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.</ArticleTitle>
        <Pagination>
          <StartPage>20406207221097780</StartPage>
          <MedlinePgn>20406207221097780</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">20406207221097780</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/20406207221097780</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) show good responses to frontline steroids. About two-third of cases relapse and require second-line treatment, including rituximab, mainly effective in AIHA, and thrombopoietin-receptor agonists (TPO-RAs) in ITP, while the use of splenectomy progressively decreased due to concerns for infectious/thrombotic complications. For those failing second line, immunosuppressants may be considered.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The aim of this study was to evaluate the efficacy of cyclosporine treatment in patients with ITP and AIHA.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">In this retrospective study, we evaluated the efficacy and safety of cyclosporine A (CyA) in ITP (<i>N</i> = 29) and AIHA (<i>N</i> = 10) patients followed at two reference centers in Milan, Italy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Responses were classified as partial [Hb &gt; 10 or at least 2 g/dl increase from baseline, platelets (PLT) &gt; 30 × 10<sup>9</sup>/l with at least doubling from baseline] and complete (Hb &gt; 12 g/dl or PLT &gt; 100 × 10<sup>9</sup>/l) and evaluated at 3, 6, and 12 months. Treatment emergent adverse events were also registered.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The median time from diagnosis to CyA was 35 months (3-293), and patients had required a median of 4 (1-8) previous therapy lines. Median duration of CyA was 28 (2-140) months and responses were achieved in 86% of ITP and 50% of AIHA subjects. Responders could reduce or discontinue concomitant treatment and resolved PLT fluctuations on TPO-RA. CyA was generally well tolerated, and only two serious infectious complications in elderly patients on concomitant steroids suggesting caution in this patient population.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">CyA may be advisable in ITP, which is not well controlled under TPO-RA, and in AIHA failing rituximab, particularly if ineligible in clinical trial.</AbstractText>
          <CopyrightInformation>© The Author(s), 2022.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fattizzo</LastName>
            <ForeName>Bruno</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-0857-8379</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, via F. Sforza 35, 20100 Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cantoni</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Hematology &amp; Oncology Department, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giannotta</LastName>
            <ForeName>Juri Alessandro</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0001-9349-1627</Identifier>
            <AffiliationInfo>
              <Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bandiera</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, Hematology &amp; Oncology Department, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zavaglia</LastName>
            <ForeName>Rachele</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Hemato-Oncologyilan, University of Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bortolotti</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Hemato-Oncologyilan, University of Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barcellini</LastName>
            <ForeName>Wilma</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ther Adv Hematol</MedlineTA>
        <NlmUniqueID>101549589</NlmUniqueID>
        <ISSNLinking>2040-6207</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Evans syndrome</Keyword>
        <Keyword MajorTopicYN="N">autoimmune hemolytic anemia</Keyword>
        <Keyword MajorTopicYN="N">cyclosporine A</Keyword>
        <Keyword MajorTopicYN="N">immune thrombocytopenia</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.F. received consultancy from Apellis, Momenta, and Novartis and lecture fee or congress support from Alexion and Apellis. W.B. received consultancy from Agios, Alexion, Apellis, Biocryst, Bioverativ, Incyte, Momenta, and Novartis and lecture fee or congress support from Alexion, Incyte, Novartis, and Sanofi.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>2</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35585968</ArticleId>
        <ArticleId IdType="pmc">PMC9109490</ArticleId>
        <ArticleId IdType="doi">10.1177/20406207221097780</ArticleId>
        <ArticleId IdType="pii">10.1177_20406207221097780</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Berentsen S, Barcellini W. Autoimmune hemolytic anemias.
N Engl J Med
2021; 385:
1407–1419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34614331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Neunert C, Terrell DR, Arnold DM, et al.. American Society of
Hematology 2019 guidelines for immune thrombocytopenia [Erratum in:
Blood Adv 2020; 4: 252]. Blood
Adv
2019; 3:
3829–3866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6963252</ArticleId>
            <ArticleId IdType="pubmed">31794604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Birgens H, Frederiksen H, Hasselbalch HC, et al.. A phase III randomized trial
comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in
patients with autoimmune haemolytic anaemia. Br J
Haematol
2013; 163:
393–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23981017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moulis G, Palmaro A, Montastruc JL, et al.. Epidemiology of incident
immune thrombocytopenia: a nationwide population-based study in
France. Blood
2014; 124:
3308–3315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25305203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Michel M, Terriou L, Roudot-Thoraval F, et al.. A randomized and
double-blind controlled trial evaluating the safety and efficacy of
rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA
study). Am J Hematol
2017; 92:
23–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27696475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jäger U, Barcellini W, Broome CM, et al.. Diagnosis and treatment of
autoimmune hemolytic anemia in adults: recommendations from the First
International Consensus Meeting. Blood Rev
2020; 41: 100648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31839434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bradbury CA, Pell J, Hill Q, et al.. Mycophenolate mofetil for
first-line treatment of immune thrombocytopenia. N
Engl J Med
2021; 385:
885–895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34469646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic use in immunoregulatory
disorders [Erratum in: Drugs 1993; 46:
377]. Drugs
1993; 45:
953–1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7691501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moskowitz IP, Gaynon PS, Shahidi NT, et al.. Low-dose cyclosporin A
therapy in children with refractory immune thrombocytopenic
purpura. J Pediatr Hematol Oncol
1999; 21:
77–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10029820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gesundheit B, Cividalli G, Freeman A, et al.. Cyclosporin A in the
treatment of refractory immune thrombocytopenia purpura in
children. Eur J Haematol
2001; 66:
347–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11422416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hlusi A, Szotkowski T, Indrak K. Refractory immune thrombocytopenia. Successful
treatment with repeated cyclosporine A: two case reports.
Clin Case Rep
2015; 3:
337–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4498837</ArticleId>
            <ArticleId IdType="pubmed">26185623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baratta L, Golluscio V, Delfino M. Efficacia del trattamento con ciclosporina A in
paziente con anemia emolitica autoimmune resistente a terapia con steroidi
[Favorable response to cyclosporin A in a patient with steroid resistant
autoimmune haemolytic anaemia]. Recenti Prog
Med
2004; 95: 100. (in
Italian)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15074296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Janić D, Krivokapić-Dokmanović L, Jovanović N, et al.. Glucocorticoid-resistant
Evans’ syndrome successfully controlled with low-dose
cyclosporine. Int J Clin Pharmacol Ther
2011; 49:
622–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21961487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sarper N, Çakı Kılıç S, Zengin E, et al.. Management of autoimmune
hemolytic anemia in children and adolescents: a single center
experience. Turk J Haematol
2011; 28: 198–205.
(in English)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27264367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lauro A, Stanzani M, Finelli C, et al.. Alemtuzumab plus
cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel
transplant. Case Rep Transplant
2014; 2014:
262953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4142660</ArticleId>
            <ArticleId IdType="pubmed">25177510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ito M, Yagasaki H, Kanezawa K, et al.. Incidence and outcomes of
refractory immune thrombocytopenic purpura in children: a retrospective
study in a single institution. Sci Rep
2021; 11: 14263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8275793</ArticleId>
            <ArticleId IdType="pubmed">34253777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rackoff WR, Manno CS. Treatment of refractory Evans syndrome with
alternate-day cyclosporine and prednisone. Am J
Pediatr Hematol Oncol
1994; 16:
156–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8166369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yarali N, Fişgin T, Kara A, et al.. Successful management of
severe chronic autoimmune hemolytic anemia with low dose cyclosporine and
prednisone in an infant. Turk J Pediatr
2003; 45:
335–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14768800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Emilia G, Morselli M, Luppi M, et al.. Long-term salvage therapy
with cyclosporin A in refractory idiopathic thrombocytopenic
purpura. Blood
2002; 99:
1482–1485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11830504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perrotta S, Amendola G, Locatelli F, et al.. Treatment with short-term,
high-dose cyclosporin A in children with refractory chronic idiopathic
thrombocytopenic purpura. Br J Haematol
2003; 121:
143–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12670345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cui ZG, Liu XG, Qin P, et al.. Recombinant human
thrombopoietin in combination with cyclosporin A as a novel therapy in
corticosteroid-resistant primary immune thrombocytopenia.
Chin Med J
2013; 126:
4145–4148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24229688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Choi PY, Roncolato F, Badoux X, et al.. A novel triple therapy for
ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine
(TT4). Blood
2015; 126:
500–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4560338</ArticleId>
            <ArticleId IdType="pubmed">25972158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thabet AF, Moeen SM. More about the combination of rituximab,
cyclosporine and dexamethasone in the treatment of chronic ITP. A useful
option on an environment with limited resources.
Platelets
2020; 31:
784–787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31603012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mousavi-Hasanzadeh M, Bagheri B, Mehrabi S, et al.. Sirolimus versus
cyclosporine for the treatment of pediatric chronic immune thrombocytopenia:
a randomized blinded trial. Int
Immunopharmacol
2020; 88: 106895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32871473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Emilia G, Messora C, Longo G, et al.. Long-term salvage treatment
by cyclosporin in refractory autoimmune haematological
disorders. Br J Haematol
1996; 93:
341–344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8639426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu H, Shao Z, Jing L. [The effectiveness of cyclosporin A in the
treatment of autoimmune hemolytic anemia and Evans
syndrome]. Zhonghua Xue Ye Xue Za Zhi
2001; 22: 581–583.
(in Chinese)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11855146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu AP, Cheuk DK, Lee AH, et al.. Cyclosporin A for persistent
or chronic immune thrombocytopenia in children. Ann
Hematol
2016; 95:
1881–1886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27525725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun F, Chen J, Wu W, et al.. Rituximab or cyclosporin in
refractory immune thrombocytopenia secondary to connective tissue diseases:
a real-world observational retrospective study. Clin
Rheumatol
2020; 39:
3099–3104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32418039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang T, He X, Ran N, et al.. Immunological
characteristics and effect of cyclosporin in patients with immune
thrombocytopenia. J Clin Lab Anal
2021; 35: e23922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8418498</ArticleId>
            <ArticleId IdType="pubmed">34329516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barcellini W, Fattizzo B, Zaninoni A, et al.. Clinical heterogeneity and
predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study
of 308 patients. Blood
2014; 124:
2930–2936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25232059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Penel Page M, Bertrand Y, Fernandes H, et al.. Treatment with cyclosporin
in auto-immune cytopenias in children: the experience from the French cohort
OBS’CEREVANCE. Am J Hematol. Epub ahead of
print 14
May
2018. DOI: 10.1002/ajh.25137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25137.</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khellaf M, Charles-Nelson A, Fain O, et al.. Safety and efficacy of
rituximab in adult immune thrombocytopenia: results from a prospective
registry including 248 patients. Blood
2014; 124:
3228–3236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25293768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghanima W, Khelif A, Waage A, et al.. Rituximab as second-line
treatment for adult immune thrombocytopenia (the RITP trial): a multicentre,
randomised, double-blind, placebo-controlled trial.
Lancet
2015; 385:
1653–1661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25662413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deshayes S, Khellaf M, Zarour A, et al.. Long-term safety and
efficacy of rituximab in 248 adults with immune thrombocytopenia: results at
5 years from the French prospective registry ITP-ritux.
Am J Hematol
2019; 94:
1314–1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31489694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fattizzo B, Pasquale R, Carpenedo M, et al.. Bone marrow characteristics
predict outcome in a multicenter cohort of primary immune thrombocytopenia
patients treated with thrombopoietin analogs.
Haematologica
2019; 104:
e470–e473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6886419</ArticleId>
            <ArticleId IdType="pubmed">30846501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fattizzo B, Zaninoni A, Gianelli U, et al.. Prognostic impact of bone
marrow fibrosis and dyserythropoiesis in autoimmune hemolytic
anemia. Am J Hematol
2018; 93:
E88–E91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29274091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Peng J. Single-cell characterization of hematopoietic
stem and progenitor cells in immune thrombocytopenia. In:
Annual Meeting of the European Hematology Association,
June
2021, Abstract number EP1627, https://library.ehaweb.org/eha/2020/eha25th/294111/yan.liu.single-cell.characterization.of.hematopoietic.stem.and.progenitor.html</Citation>
        </Reference>
        <Reference>
          <Citation>
Fattizzo B, Da Via’ MC, Giannotta JA, et al.. Dissection of bone marrow
microenvironment by single cell RNA sequencing in warm AIHA patients: a
proof-of-concept analysis. In: Annual Meeting of
the American Society of Hematology, Atlanta,
GA, December 2021, Abstract number
931.</Citation>
        </Reference>
        <Reference>
          <Citation>
Marangon M, Vianelli N, Palandri F, et al.. Rituximab in immune
thrombocytopenia: gender, age, and response as predictors of long-term
response. Eur J Haematol
2017; 98:
371–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27981682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pavord S, Thachil J, Hunt BJ, et al.. Practical guidance for the
management of adults with immune thrombocytopenia during the COVID-19
pandemic. Br J Haematol
2020; 189:
1038–1043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7267627</ArticleId>
            <ArticleId IdType="pubmed">32374026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giannotta JA, Fattizzo B, Cavallaro F, et al.. Infectious complications in
autoimmune hemolytic anemia. J Clin Med
2021; 10: 164.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
